Resection/Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma
Recruiting · Not applicable · NCT07340151
Conditions: Adenocarcinoma of the Pancreas
At a glance
- Research payments reported, 2025
- $393,547
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 40
About the trial
- Sponsor
- The University of Texas Health Science Center at San Antonio (with Ipsen)
- Tested
- Surgical resection (procedure)
- Dates
- Started 2026-03-02; completion 2028-12
- Results posted
- Not yet
This is a clinical trial that tests a surgical treatment. Everyone in the study will get the same treatment, and there is no comparison or placebo group. Patients can join the study if they have pancreatic cancer that has spread to only a few spots in the liver or lungs. They must be receiving a type of chemotherapy called NALIRIFOX before surgery (this is called neoadjuvant chemotherapy). If the cancer gets worse during or after the first 4 cycles of chemotherapy, the patient will be removed from the study. If the cancer stays the same or gets smaller after the first 4 cycles, doctors will check if the main tumor can be removed with surgery. If the tumor cannot be removed, the patient wi…
From ClinicalTrials.gov, last updated 2026-04-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ipsen Biopharmaceuticals, Inc reported $393,547 in research payments for this study in 2025 (2 payments).
Products named: Onivyde
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut Health San Antonio MD Anderson Cancer Center $393,547
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.